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Abstract
Salivary diagnostics plays an important role in the early detection and prevention of many
oral and systemic diseases in a fast and noninvasive way. Saliva collection is an easy,
repeatable and inexpensive diagnostic source that can be used for both diagnosis and
real-time monitoring of various human diseases. In the near future, many developed and
validated salivary biomarkers have the potential to reach the clinical practice. Five diag-
nostic “omics” constituents of saliva include proteomics, transcriptomics, metabolomics,
microbiomics and microRNAs. Based on them, the newly emerging technologies of sali-
vary diagnostics are developed that include RNA-sequencing, point-of-care technologies
and liquid biopsy. They have potential to enable screening, early detection, prognosis and
monitoring of various human diseases. The recent developments broadened the salivary
diagnostic approach from the oral cavity to the whole physiological system, thus toward
personalized individual medicine applications.
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1. Introduction
Saliva is an encouraging medium to be used in the early detection, diagnosis and monitoring
of oral and systemic diseases, specifically for the purpose of personalized medicine by incor-
porating point-of care technology platforms in the clinical settings. Though, saliva collection is
easy, fast, cheap, safe, does not require specialized equipment and can be performed at home
[1]. The normal daily production of saliva varies between 0.5 and 1.5 l. Saliva is an acidic
biofluid, derived from the three major salivary glands (parotid, submandibular, sublingual) as
well as from minor glands (labial, buccal, lingual, and palatal tissues). It is composed in vast
majority of water (99%), while other constituents occur in trace amounts, including proteins
and both inorganic (sodium, potassium, calcium, magnesium, chloride, etc.) and organic
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constituents (amylases, peroxidase, lipase, mucins, lysozyme, lactoferrins, cystatins, hormones,
etc.) [2]. Salivary composition is very diverse (RNA, DNA, proteins, metabolites, and micro-
biota), and may be utilized for diagnostic purposes. Most importantly, salivary components
may vary in their concentrations and levels depending on the individual’s health or disease
status. Thus, real-time monitoring of salivary data can provide useful translational clinical
applications in the detection of various human oral and systemic diseases. The development
of the recent technologies based on salivary diagnostics will help to introduce screening pro-
grams to enable early detection and monitoring of the disease [3].
Saliva is an important biofluid with lots of various biological functions including lubrication,
chewing, swallowing, sensation, digestion and protection of oral mucosa against biological,
mechanical, and chemical factors as well as infections [2].
2. Salivaomics
Currently, there are known five major diagnostic toolboxes of saliva “Salivaomics”: proteomics
(the study of proteins), transcriptomics (the study of RNAs), metabolomics (the study of
metabolites), microRNA (the study of microRNAs) and microbiome (the study of microbiota)
[1, 2] (Figure 1).
2.1. Proteomics
The proteomics is the large-scale screening for proteins, their expression, modifications, and
interactions by using high-throughput approaches [4, 5]. Proteins can indicate various physio-
logical and pathological states of the current health condition or specific disease. The recent
advancements in proteomics contributed to the development of new non-invasive technologies.
Figure 1. Diagnostic toolboxes of saliva.
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The currently accepted gold standard methods for proteomic analyses include: triple depletion
of high abundance proteins (removal of albumins, alpha amylase and immunoglobulins),
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE), two-dimensional gel
electrophoresis (2-DE), mass spectrometry (label free qMS), ELISA (enzyme-linked immunosor-
bent assay) andWestern blotting [2, 6]. Other advanced methods include electrospray ionization
(ESI), matrix-assisted laser desorption ionization (MALDI), quadrupole/linear ion trap, time-of-
flight (TOF), quadrupole TOF (QTOP), Fourier transform ion cyclotron resonance (FT-ICR), or
the OrbiTrap, MS/MS, MALDI-MS or targeted HPLC-ESI-MS/MS [7].
Recently, a great focus has been put on identification of salivary protein biomarkers for various
human oral and systemic diseases such as: pancreatic cancer, Sjogren’s syndrome, oral cancer,
lung cancer, orthodontically induced root resorption, etc. [2, 5]. The proteomics delivers an
alternative ideal and non-invasive diagnostic tool, more sensitive, and safer for detecting the
disease status. In addition, the depletion of high abundance proteins from saliva contributes to
significant increase in the detectability of less abundant salivary proteins [5, 8]. There are
known three major methods of high-abundance protein removal [9]: enzyme-substrate absorp-
tion method used for alpha-amylase affinity removal [8], immunodepletion method and com-
binatorial peptide ligand library (CPLL) [10].
Proteomic analysis of saliva is commonly used in the diagnostics of oral diseases as well as
general health disorders such as oral candidiasis [11], oral squamous cell carcinoma (OSCC)
[12], glossodynia [13], head and neck squamous cell cancer [14], Sjögren’s syndrome [15], HIV
[11], autism [16], fibromyalgia [17], breast cancer [18], lung cancer, melanoma [19] or pancre-
atic cancer [7].
Various mediators associated with oral cancer are released from cells due to malignant condi-
tions and have been analyzed in saliva samples, like cytokines, chemokines, interferon-gamma
(IFN-γ), interleukins (IL-1β, IL-6 and -8, Il-4 and -10), tumor necrosis factors (TNF-α),
transforming growth factor-beta-1 (TGF-β1), epidermal growth factor (EGF), vascular endo-
thelial growth factor (VEGF), and endothelin [20]. In case of oral squamous cell carcinoma,
elevated levels of NF- κB-dependent cytokines have been observed in saliva [21]. Other poten-
tial protein biomarkers include IL-6 and S100A9 [22] or BGH3, MMP9 and PDIA3 [23]. In
addition, increased salivary expression levels of MMP1 and MMP3 in OSCC patients can
indicate more advanced stage of disease [12], while adenosine deaminase might be indicative
of early stage of oral tongue cancer [24].
2.2. Transcriptomics
Transcriptomics (gene expression profiling) is the quantitative study of an organism’s trans-
criptome, all RNA transcripts present in a cell. The information is recorded in the genome and
expressed through transcription. These data can be used for capturing marked changes in
expression levels of specific genes in the detection of various human diseases [2, 25].
Transcriptomics encompasses a great diversity of RNA species including messenger RNAs
(mRNAs), long non-coding RNAs (lncRNAs), and small RNAs such as microRNAs (miRNAs),
transfer RNAs (tRNAs), piwi-interacting RNA (piRNA), etc. The mRNAs play an important
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role in carrying information for making proteins while noncoding RNAs have different func-
tions [25]. In turn, the microRNAs (miRNAs) are a group of small non-coding RNAs that
regulate mRNA through sequence-specific binding to the UTR [26]. The miRNAs are involved
in various biological processes.
The common practice in identification of salivary transcriptomic biomarkers is microarray
technology. However, this technology is currently replaced by the newer one, RNA-sequencing
(RNA-Seq).
2.2.1. RNA sequencing
RNA-sequencing (RNA-Seq) has been the newly developed method for characterizing the full
human transcriptome. RNA-sequencing (RNA-Seq) has a wide variety of applications, but no
single analysis pipeline can be used in all cases and for all biofluids [27]. Specifically, RNA-Seq
of saliva is challenging, including difficult RNA isolation step to enhance yield of salivary
exRNA step as well as laborious RNA-Seq small and large library construction stage, inclusion
of spike in standards and controls, RNA-sequencing, data storage and data analysis. There-
fore, currently available literature regarding salivary RNA-Seq is scarce [28–30].
RNA-sequencing is a rapidly progressing transcriptome profiling that uses deep-sequencing
technologies and becoming the major tool in analyzing gene expression [31]. This is a new
high-throughput method for both mapping and quantifying transcriptomes. It provides more
detailed information about the levels of transcripts and their isoforms than other methods [32].
In general, a total RNA is converted to a library of cDNA fragments with adaptors attached to
one or both ends. Afterwards, a sequencing of the molecule is performed, with or without
amplification, that provides short sequences from one (single-end sequencing) or both ends
(pair-end sequencing). The reads are typically 30–400 bp, depending on the DNA-sequencing
technology used. Revealing the transcriptome is crucial for investigating the functional ele-
ments of the genome, the molecular constituents of cells and tissues, and also for understand-
ing development and disease [32].
2.2.1.1. Advantages of RNA sequencing
RNA- Seq (RNA sequencing) has clear advantages over existing approaches and is believed to
become the best method for analyzing transcriptome in the near future.
Firstly, RNA-Seq can be used for detection of both known (corresponding to existing genomic
sequences) and novel transcripts, thus enabling identification of new organisms with
unidentified yet genomic sequences. RNA-Seq is used for precise localization of transcription
boundaries, to a single-base resolution. Furthermore, this method can be used for examining
transcripts of great complexity as it provides useful information about the connectivity of
exons as well as sequence variations in the transcribed regions [33–34].
Secondly, RNA-Seq has very low, if any, background signal. This feature differentiates it
significantly from microarray platforms as it can be uniquely mapped to the genome regions
of interests [35].
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RNA-Seq has also significant benefits over array-based technologies for detecting expression
quantitative trait loci (eQTLs). Though, it can identify different transcript variants and enable
quantification of allele-specific expression within an individual to increase association map-
ping [27, 36, 37].
Finally, it has a highly accurate and large dynamic range of expression levels with high
reproducibility rates while using less RNA sample and at a much lower cost than either tiling
arrays or large-scale Sanger EST Sequencing [33, 35].
2.2.1.2. Disadvantages of RNA sequencing
The major problems of RNA-Seq technology are associated with RNA isolation and cDNA
library construction as it includes several manipulation stages, which can complicate profiling
of transcripts of various lengths [32]. This causes the variability in the measurements,
influenced by the technical noise [27].
In addition, longer RNAs have to be fragmented into smaller pieces (200–500 bp) to be compat-
ible with most deep-sequencing technologies using RNA or cDNA fragmentation methods
(RNA hydrolysis or nebulization, DNase I treatment, etc.) [33, 35]. These sequencing procedures
include a number of steps (RNA fragmentation, cDNA synthesis, adapter ligation, PCR amplifi-
cation, bar-coding, and lane loading) that might introduce biases into the resulting data [27].
Another key consideration concerning library construction is whether or not to construct
strand- specific libraries [33, 38], that provide information about the orientation of transcripts,
essential for transcriptome annotation. However, strand-specific libraries are very time-
consuming to produce [39, 40].
RNA-Seq has also bioinformatics challenges associated with storage, retrieval and processing
large amounts of data. The alignment of long RNA-Seq reads is also complicated due to non-
unique mapping to multiple locations in the genome [32].
Also, to detect a rare transcript or variant, more sequencing depth is needed. In general, the
larger the genome, the more sequencing depth is required for adequate coverage, which brings
greater cost [32].
Although RNA-Seq is still in the early stages of use, it has clear advantages over previously
developed transcriptomic methods such as microarray profiling [32]. Specifically, salivary
RNA biomarker transcripts of IL8, IL1B, DUSP1, HA3, OAZ1, S100P, and SAT yielded high
sensitivity (91%) and specificity (91%) in distinguishing OSCC from the controls [41]. Also,
salivary IL6 mRNA and IL-8 may serve as potential biomarkers for diagnosis of OSCC [42, 43].
2.2.2. Difficulties in salivary RNA-sequencing and bioinformatic analysis
RNA-sequencing (RNA Seq) of saliva is challenging compared to other biofluids such as blood
or urine. RNA Sequencing of salivary samples is associated with several problems such as
inadequate technique of RNA isolation, improper stabilization of RNA or RNA library con-
struction [44–48]. Till now, there were also no established guidelines how to bioinformatically
process the salivary RNA-Seq data. The recent paper by Kaczor-Urbanowicz et al. gives the
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recommendations for bioinformatics analysis of salivary RNA-Seq data that differs from other
biofluids (blood, urine, etc.) as saliva contains the majority of microbial content, while other
physiological fluids are considered to be sterile [48]. Thus, it is recommended to use quite
stringent and sensitive criteria, while working with salivary RNA-Seq data to avoid errone-
ously mapped bacterial reads to the human genome, and to prevent problems with their
further annotation to human RNA databases. In addition, the specific sequence of alignment
steps and the stringency parameters associated with processing of RNA Sequencing data can
grossly increase the final data quality [48].
2.3. Micro-RNA-omics
MicroRNAs (miRNAs) are short, single-stranded RNAs that are about 21 nucleotides in length.
Their function is to regulate gene expression. Like other types of RNA, miRNAs are transcribed
from DNA, but they do not participate in protein translation. They are non- coding RNAs, in
which each primary transcript (pri-miRNA) is processed into a pre-miRNA and finally into
functional miRNA [49]. Mature miRNA are involved in various biological processes such as cell
growth, differentiation, apoptosis, stress and immune response or glucose secretion [50–52].
Studies on miRNA dysregulation in various human diseases have risen rapidly in recent years,
including those in cancer, heart disease as well as type II diabetes mellitus and its complications,
such as endothelial and vascular smooth muscle cell dysfunction, cardiomyopathy and nephrop-
athy [53–55]. Most importantly, salivary microRNAs (miRNAs) (miR-9, miR-134 and miR-191)
can be used as potential biomarkers for head and neck squamous cell carcinoma [56]. The
reduction in salivary expression profiles of miR-125a and miR-200a was observed in OSCC
patients compared to healthy people [57]. In turn, miR-31 increases in OSCC patients, specifi-
cally in saliva, where it rises even more than in plasma [58].
2.4. Metabolomics
Metabolomics is the study of small molecular metabolites of living tissues, mostly metabolic
intermediates such as carbohydrates, lipids, amino acids, nucleic acids, etc. [1]. The major
metabolomic technologies include high-performance liquid chromatography-mass spectrome-
try (HPLC-MS), two-dimensional gas chromatography MS and nuclear magnetic resonance
spectroscopy in conjunction with pattern recognition methods [2].
Salivary metabolites are involved in many biological processes as well as pathogenesis of
various diseases such as periodontal diseases, renal diseases, hepatocellular carcinoma and
colorectal cancers [59] as well as oral cancer [60]. In case of oral leukoplakia, an upregulation of
putrescine, 8-hydroxyadenine and 5,6-dihydrouridine in OSCC can be indicative of increased
risk for malignant transformation [61].
2.5. Microbiomics
Microbiomics include study of bacteria, archaea, protists, fungi and viruses. Microbial profil-
ing (Human Oral Microbe Identification Microarray) of salivary microbiome in early resectable
pancreatic cancer revealed that Neisseria elongata and Streptococcus mitis were successfully
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developed with 96.4% sensitivity and 82.1% specificity [62]. Currently, newer microbiome-
based technologies have been developed such as RNA or DNA sequencing [1]. In addition,
two microbial biomarkers, Firmicutes (especially Streptococcus) and Actinobacteria (espe-
cially Rothia) were significantly decreased in oral cancer compared to healthy controls [63].
Finally, Furquim et al. reported that patients with Fanconi anemia (FA) are at higher risk of
developing OSCC than the general population, especially after the hematopoietic stem cell
transplantation [64].
3. Modern technologies in salivary diagnostics
3.1. Salivary liquid biopsy
Recently, a new trend appeared to reveal emerging role of “liquid biopsy” as identification
method of biomarkers in various cancers. Liquid biopsy tests are non-invasive biofluid tests
(serum, urine, saliva) that detect circulating tumor cells (CTCs) and fragments of tumor DNA
shed into the bloodstream by cells undergoing apoptosis or necrosis [3].
The role of liquid biopsy markers including circulating tumor cells, circulating RNAs (miRNA,
lncRNAs and mRNAs), cell-free proteins, peptides and exosomes has been currently investi-
gated as non-invasive cancer biomarkers in different biofluids such as blood, urine, saliva and
seminal plasma. Liquid biopsies hold great promise for personalized medicine due to the fact
that they enable multiple non-invasive global sampling resulting in longitudinal assessment of
the primary and metastatic tumors. Molecular profiling of circulating molecules (proteomic,
transcriptomic, genomic, metabolomics, microRNAs) contributed to the successful application
of several non-invasive multi-marker tests in the clinic [65].
Nowadays, liquid biopsy enables a variety of clinical and investigational applications such as
early detection, assessment of molecular heterogeneity of general disease, monitoring of tumor
dynamics (in melanoma, breast, ovarian or colon cancers), identification of genetic determi-
nants for targeted therapy, evaluation of early treatment response, monitoring of minimal
residual disease or assessment of resistance evolution in real time [66].
The most common technologies of liquid biopsy include detection and quantification of
ctDNA (circulating tumor DNA) in blood such as Sanger sequencing, pyrosequencing, next
generation sequencing, PCR-based technology, high-performance liquid chromatography
(HPLC), mutant-enriched liquid chips, amplification refractory mutation system (ARMS),
beads, emulsion, amplification and magnetics (BEAMing), pyrophosphorolysis-activated poly-
merization (PAP) [2, 66] or electric field-induced release and measurement (EFIRM) [67, 68]. The
current gold standard methods for detection of ctDNA targets include droplet digital PCR and
next-generation sequencing. However, those technologies require extraction of DNA from large
volume of biofluid samples. EFIRM can be successfully used for continuous monitoring during
treatment. The results are very promising [3].
Circulating tumor DNA (ctDNA) is considered to be stably found in biofluids encapsulated in
extracellular vesicles (EVs) and released by cells into the circulation. If the links between distal
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cancers and the oral cavity will appear to be scientifically proven, it will open a new avenue of
clinical utility to effectively, and non-invasively diagnose cancers through saliva. The ctDNA
mutant fragments were observed in plasma [69, 70] and saliva samples [71] of head and neck
cancer patients.
3.2. Point-of-care technologies
The current knowledge of salivary biomarkers and their role in point-of-care applications
highlights the need for development of more advanced technologies. As a consequence,
point-of-care diagnostics is definitely approaching reality for salivary research and closely
related with its translation into clinical practice [3] as it delivers information of the current
status of the disease in a very fast, convenient and non-invasive way. PoCs can be successfully
used for early detection and real-time monitoring of the disease [3].
The current PoC technologies are ubiquitous. They comprise microfluidics, micro/nanoelectro-
mechanical systems (MEMS/NEMS), paper-based technology, RNA-sequencing, liquid biopsy,
biosensors, fluorescent biosensors, photometric and electrochemical methods, electronic nose
and electric field-based methods such as electric field-induced release and measurement
(EFIRM) method [3, 68, 72]. Contemporary available PoCs can be delivered in form of small
and portable smartphones or “lab-on-chips” [3].
One of such PoC development is the Oral Fluid NanoSensor Test (OFNASET), that is used for
multiplex detection of salivary proteomic (thioredoxin and IL-8) and genomic biomarkers (mes-
senger RNA biomarkers, i.e. SAT, ODZ, IL-8, and IL-1b) for oral cancer with 90% sensitivity and
90% specificity for both interleukin 8 (IL-8) and IL-8 protein messenger RNA (mRNA) [67]. In
turn, OraRisk human papilloma virus (HPV) test with Reflex (Quest Diagnostics, Los Angeles,
CA, USA) can be indicative of HPV infection, high risk factor for development of oral cancer [68].
In addition, electrical controlled magnetic EC Sensor is designed to detect microRNA-200a [73],
electrochemical sensor using endonuclease target recycling amplification to capture oral cancer
overexpressed 1 (ORAOV1) [74], while wireless mouthguard enzymatic biosensor to detect uric
acid [75] or lactic acid [76], potential biomarkers for oral cancer.
4. Conclusions
Salivary diagnostics is a promising field for the implementation of PoC technology. The desire
for PoC, the potential of saliva, development of validated panel of salivary biomarkers for
specific diseases and development of novel advanced techniques enables the application of
saliva for the early detection and diagnosis of several oral and systemic diseases in a non-
invasive, easy and fast personalized way. The recent technology advances, including liquid
biopsy, EFIRM, biosensors, smartphones, microfluidics, paper-based technology, have the
potential to make clinical utilities of saliva a reality in the near future. Saliva is predicted to be
a substitute for blood, collected non-invasively for the diagnosis of oral and systemic diseases
as well as chairside screening.
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